top of page
Browse by category
Search


Ascletis reveals pharmacokinetic and weight loss data from its ASC47 Phase Ib single subcutaneous injection
Ascletis Pharma has announced pharmacokinetic and weight loss data from its ASC47 Phase Ib single subcutaneous injection studies in...


Muscle-preserving weight loss drug ASC47 plus semaglutide is superior to semaglutide monotherapy for weight loss
Ascletis Pharma has revealed in a head-to-head diet-induced obese (DIO) mouse study, ASC47 low dose combination 1 (ASC47, 3 mg/kg,...
Browse by tag





bottom of page